
Glucodent Ltd, through the company Maiwald GmbH, has submitted a patent application to the European Patent Office to protect its intellectual property.

This is the first patent application has been submitted by Glucodent. The patent covers a synthesized molecule that forms the foundation of Glucodent's future medical product.

The patent was submitted to European patent office by Maiwald GmbH.

A second patent application, which will protect the formulation and intended use of the final product, is planned to follow shortly.

Filing for patent protection is a crucial legal step that enables the continued development of the medical product under Glucodent's innovation pipeline.

By securing this patent, Glucodent ensures protection of the intellectual property it has developed.

Importantly, the submission of both patent applications will pave the way for the next key phase in product development – clinical testing.

Glucodent aims to initiate clinical trials in the first half of 2025.

Glucodent Ltd. is an advanced research and development project focused on creating a specialized product for oral pathology intended for people with diabetes. Our mission is to improve the oral health and well-being of diabetics through an innovative and scientifically validated product.

The project relies on the expertise of leading scientific institutions and our distinguished team of scientists. Additionally, we collaborate with experts in key areas such as intellectual property (IP), legal affairs, regulatory compliance, and strategic consulting. This comprehensive approach ensures that our product not only achieves efficacy but also meets the highest quality standards.